JP2016510797A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510797A5
JP2016510797A5 JP2015562215A JP2015562215A JP2016510797A5 JP 2016510797 A5 JP2016510797 A5 JP 2016510797A5 JP 2015562215 A JP2015562215 A JP 2015562215A JP 2015562215 A JP2015562215 A JP 2015562215A JP 2016510797 A5 JP2016510797 A5 JP 2016510797A5
Authority
JP
Japan
Prior art keywords
alkyl
het
independently
cycloalkyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015562215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055168 external-priority patent/WO2014140313A1/en
Publication of JP2016510797A publication Critical patent/JP2016510797A/ja
Publication of JP2016510797A5 publication Critical patent/JP2016510797A5/ja
Ceased legal-status Critical Current

Links

JP2015562215A 2013-03-15 2014-03-14 大環状塩誘導性キナーゼ阻害剤 Ceased JP2016510797A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2013/055389 2013-03-15
EP2013055389 2013-03-15
PCT/EP2014/055168 WO2014140313A1 (en) 2013-03-15 2014-03-14 Macrocyclic salt-inducible kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2016510797A JP2016510797A (ja) 2016-04-11
JP2016510797A5 true JP2016510797A5 (enExample) 2017-03-30

Family

ID=50588637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562215A Ceased JP2016510797A (ja) 2013-03-15 2014-03-14 大環状塩誘導性キナーゼ阻害剤

Country Status (13)

Country Link
US (1) US9586975B2 (enExample)
JP (1) JP2016510797A (enExample)
KR (1) KR20150133767A (enExample)
CN (1) CN105209040A (enExample)
AU (1) AU2014230125A1 (enExample)
BR (1) BR112015022650A8 (enExample)
CA (1) CA2906262A1 (enExample)
EA (1) EA201591794A1 (enExample)
HK (1) HK1219057A1 (enExample)
IL (1) IL241325A0 (enExample)
MX (1) MX2015012528A (enExample)
SG (1) SG11201507493SA (enExample)
WO (1) WO2014140313A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014230111A1 (en) * 2013-03-15 2015-10-29 Oncodesign S.A Macrocyclic RIP2 kinase inhibitors
AU2015292818B2 (en) 2014-07-21 2020-01-16 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
CA3069016A1 (en) 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
AU2018226771B2 (en) 2017-02-28 2023-11-23 Dana-Farber Cancer Institute, Inc. Uses of pyrimidopyrimidinones as SIK inhibitors
EP3391907B8 (en) 2017-04-20 2020-03-04 iOmx Therapeutics AG Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof
WO2019120267A1 (zh) * 2017-12-22 2019-06-27 成都先导药物开发股份有限公司 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
WO2020027200A1 (ja) 2018-08-01 2020-02-06 小野薬品工業株式会社 軟骨関連疾患治療剤
US11690897B2 (en) 2019-02-04 2023-07-04 The Board Of Trustees Of The University Of Illinois Salt inducible kinase inhibitors for enhancing fertility
UY39061A (es) * 2020-01-31 2022-01-31 Oncodesign Sa Inhibidores macrocíclicos de rip2-cinasa
CN117659043A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种大环咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
SG48049A1 (en) 1993-10-01 1998-04-17 Astra Ab Process i
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
CN101600718B (zh) * 2006-11-06 2013-07-03 特雷罗药物股份有限公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
EP2300469B1 (en) * 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
UA113186C2 (xx) * 2011-09-30 2016-12-26 Макроциклічні інгібітори lrrk2 кінази
EA025881B1 (ru) * 2011-09-30 2017-02-28 Онкодизайн С.А. Макроциклические ингибиторы flt3-киназы

Similar Documents

Publication Publication Date Title
JP2016510797A5 (enExample)
JP2016510796A5 (enExample)
JP2017529365A5 (enExample)
JP2019536785A5 (enExample)
RU2014117515A (ru) Макроциклические ингибиторы киназы lrrk2
RU2012148246A (ru) 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ
RU2012119488A (ru) Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором
JP2019512505A5 (enExample)
CN108137590B (zh) 作为mdm2-p53抑制剂的新的螺(3h-吲哚-3,2′-吡咯烷)-2(1h)-酮化合物及其衍生物
JP2016531858A5 (enExample)
JP2017511815A5 (enExample)
JP2016523270A5 (enExample)
JPWO2020122093A5 (enExample)
JP2018515525A5 (enExample)
JP2016530262A5 (enExample)
JP2013523884A5 (enExample)
AR064155A1 (es) Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
JP2012511588A5 (enExample)
JP2019522055A5 (enExample)
JP2016525136A5 (enExample)
JPWO2019213526A5 (enExample)
JP2017512833A5 (enExample)
JP2017505762A5 (enExample)
JP2011522866A5 (enExample)
JP2009530410A5 (enExample)